Company intelligence / Profile preview

TCA Cellular Therapy

Covington, Louisiana, United Statestcacellulartherapy.com ↗

Ownership: Private
Employees: ~15
Development stage: Phase 3

Overview

The company developed autologous adult stem cell therapies targeting cardiovascular and neurological diseases. Their lead product MESENDO reached Phase II trials for ischemic heart/lower limb conditions but was ultimately discontinued or suspended. Other programs targeting ALS and spinal cord injuries were also discontinued or left pending. No products have reached commercialization as of the latest updates from ~2020–2023 sources.

Therapeutic areas: CardiovascularNeurology
Modalities: Autologous adult stem cellsMesenchymal stem cell therapiesCombination and single adult stem cell therapies
Industry: Biotech

Drug pipeline

3 assets

Mesendo

2 more assets in the full pipeline.

Partnerships

Alliantgroup assisted with grant applications/tax credits; no major pharma partnerships disclosed.

Beyond the preview

Go deeper on TCA Cellular Therapy.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TCA Cellular Therapy.